Compare PRVA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | TWST |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2021 | 2018 |
| Metric | PRVA | TWST |
|---|---|---|
| Price | $21.50 | $47.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | $30.50 | ★ $48.75 |
| AVG Volume (30 Days) | 653.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,736,390,000.00 | $376,572,000.00 |
| Revenue This Year | $23.19 | $18.89 |
| Revenue Next Year | $13.51 | $15.28 |
| P/E Ratio | $197.27 | ★ N/A |
| Revenue Growth | 4.74 | ★ 20.32 |
| 52 Week Low | $18.78 | $23.30 |
| 52 Week High | $26.51 | $57.88 |
| Indicator | PRVA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 56.28 |
| Support Level | $19.54 | $25.67 |
| Resistance Level | $24.04 | N/A |
| Average True Range (ATR) | 0.73 | 3.06 |
| MACD | 0.01 | -0.43 |
| Stochastic Oscillator | 27.50 | 30.76 |
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.